nancies, autografting is not the final step in the overall management of myeloma, 4 and post-autograft relapse can be treated effectively. 3,4 Eighteen extensively pre-treated patients (35-73 years, median 46) with relapsed multiple myeloma received Amongst 94 patients receiving salvage therapy for relapse following an autograft, 53 received standard-dose salvage chemotherapy with 6 g/m 2 cyclophosphamide, 800 mg/m 2 carboplatin, and 1800 mg/m 2 etoposide therapy and 41 received transplants. 3 With a median followup of 11 months from salvage therapy, the actuarial overall (CCV) as a 96-h continuous infusion followed by autologous peripheral blood stem cells. The median number survival at 18 months for all patients was 59%, with presalvage ␤ 2 -microglobulin р2.5 mg/l and late relapse after of prior chemotherapy regimens was five (range 4-10), including at least one autograft. Four patients died of the preceding transplant (Ͼ12 months) favorably affecting overall survival in multivariate analysis. Transplantation toxicity, and one developed dialysis-dependent renal failure, while the others tolerated CCV well. Three of performed as primary salvage therapy was associated with a significantly prolonged survival, 3 although this may be six patients with pre-transplant creatinine of Ͼ1 mg/dl died of toxicity compared with one of 12 with creatinine more a reflection of the way salvage therapy was selected because clinically symptomatic patients usually received р1 mg/dl (P = 0.083, Fisher's exact test). Three of four patients treated with four previous regimens showed standard-dose therapy whereas asymptomatic patients proceeded to a transplant immediately.
3,4
Ͼ50% reduction in tumor compared with one of 14 treated with Ͼ4 regimens (P = 0.02, Fisher's exact test).
Cyclophosphamide is an active drug in myeloma, and is included in a number of combination chemotherapy protoAt the last follow-up, five patients were alive at 8-24 months (median 13) with stable (n = 1) or progressive cols. 1, 4 However, the experience with etoposide and platinum compounds in myeloma is relatively limited.
5-13
(n = 4) disease, and nine had died of progressive disease at 2.5-15 months (median 7). We conclude that CCV Although single-agent carboplatin in standard doses has been disappointing in myeloma, 11,13 the combinations chemotherapy with autografting is tolerated well by extensively pre-treated myeloma patients provided the etoposide-dexamethasone-cytarabine-cisplatin (EDAP) 8 and cyclophosphamide-etoposide 12 have been reported to pre-transplant creatinine is normal, but toxicity in patients with abnormal renal function is high. The effibe effective in relapsed/refractory disease. We have used combination infusional chemotherapy cacy in multiply relapsed disease is poor, with response in only 22% of patients. CCV may deserve further comprising carboplatin, cyclophosphamide, and etoposide with autologous peripheral blood stem cell transplantation evaluation early in the course of myeloma in patients with normal renal function.
in 18 patients with relapsed myeloma who had received extensive previous therapy including at least one autoKeywords: autologous transplant; carboplatin; cyclophosphamide; etoposide; melphalan; multiple myeloma; transplant. relapse
Patients and methods
Despite an excellent response to sequential intensive therapy including tandem autotransplantation in a significant Eighteen patients with relapsed multiple myeloma received number of patients with multiple myeloma, 1 most patients CCV chemotherapy and an autologous peripheral blood eventually experience disease recurrence and require stem cell transplant at the University of Arkansas for Medifurther therapy.
2-4 However, unlike most other maligcal Sciences bone marrow transplant program between September 1994 and February 1996 . Patient characteristics are shown in Table 1 . Two patients, both with high-grade 
6 (33) The number of CD34 + cells infused in 17 patients was
11 (61) 0.48-34.2 × 10 6 /kg (median 3.85). One patient died of treatment-related toxicity during the conditioning before a Not including transplantation. Hemibody irradiation is included, but infusion of cryopreserved cells (see below).
local/involved field irradiation is excluded. b Includes any translocations, or any abnormalities involving chromosome 11q or 13. No karyotype results available in nine patients.
Toxicity
All patients developed grade IV hematologic toxicity. and partial remission in 13. All patients provided informed
Neutropenic fever requiring broad-spectrum antibiotic consent for the salvage chemotherapy and transplantation.
therapy developed in all patients; with bacteremia in three (one Fusobacterium and two coagulase-negative Chemotherapy and autograft Staphylococcus) and fungemia (Tinea glabrata) in one. Variable amounts of gastrointestinal toxicity (nausea, vomThe drugs were administered through an in-dwelling central iting, and diarrhea) were seen in all patients, but this was venous catheter as a continuous intravenous infusion over tolerated well. Mucositis was seen in all patients, and 96 h at the following total doses: 6 g/m 2 cyclophosphamide, required narcotic analgesics; however, it was not a major 800 mg/m 2 carboplatin, and 1800 mg/m 2 etoposide. Mesna problem. No graft-versus-host disease was seen in the was administered for uroprotection. Previously cryoprepatient receiving the pseudo-autologous graft. served autologous peripheral blood stem cells were infused Four patients died of treatment-related toxicity at days 72 h after completion of the chemotherapy infusion. The −1, 0, 3 and 10, respectively. The causes of death were day of the cell infusion was designated as day 0. All acute renal failure with congestive heart failure, cardiac patients received G-CSF (usually rounded off to 300 or 480 arrest, fluid overload with respiratory failure, and multig subcutaneously daily) from day +1 after the autograft organ failure, respectively. Acute renal failure requiring until myeloid recovery to 2 × 10 9 /l neutrophils on 2 condialysis developed in one patient, who had a baseline serum secutive days.
creatinine of 1.8 mg/dl to start with. Serum creatinine Peripheral blood stem cells were obtained in one patient increased to 2.4 mg/dl in another patient who had received when the patient had relapsed following an allograft in the 10 previous treatment regimens including one allograft and past, and were documented to be of donor origin by karyoone autograft, but this improved spontaneously. No sigtyping (male patient, female donor). In the other patients, nificant renal function abnormalities were seen in any of stem cells had been obtained prior to the first autothe other patients who did not die of toxicity. transplant.
Three of the six patients with pre-transplant creatinine levels of Ͼ1 mg/dl died of toxicity compared with one of Supportive therapy 12 with creatinine р1 mg/dl (P = 0.083, Fisher's exact test). Serious toxicity (renal failure or death) was seen in All treatment was delivered in single rooms on an in-patient four of six patients with pre-transplant creatinine levels of basis. Irradiated and leukocyte-depleted packed red cells Ͼ1 mg/dl compared with one of 12 with creatinine р1 and platelets were transfused to try to maintain a minimum mg/dl (P = 0.022, Fisher's exact test). hemoglobin of 8 g/dl and a minimum platelet count of 20 × 10 9 /l. Fever in the neutropenic phase was treated with a combination of broad-spectrum parenteral antibiotics.
Hematologic recovery
Neutrophils reached 0.5 × 10 9 /l 10-18 days (median 13) Definition of response after autografting. The time to platelet recovery (50 × 10 9 /l) was 12-288 days (median 18) in patients actually experiComplete remission was defined by the absence of monoclonal paraprotein in serum and urine using immunofixation encing platelet recovery. Eight patients died of toxicity or experienced disease progression before recovering platelets. with a normal bone marrow aspirate and biopsy. Partial
Disease response
requires intensive hydration. The toxic effects of the chemotherapy along with the fluid load contributed to early Fourteen patients not dying within 60 days of CCV and mortality in four patients. Three of these patients had autografting were considered evaluable for response. One abnormal renal function prior to the treatment. Dialysispatient attained CR, and one attained PR. Overall, four dependent renal failure developed in another patient who patients showed Ͼ50% reduction in disease bulk after had an abnormal renal function to start with. Serious tox-CCV. The best response to previous therapy among the icity (renal failure or death) was associated with preresponding patients was partial remission in three and comtransplant creatinine levels of Ͼ1 mg/dl (four of six plete remission in one. None of the other patients, including patients), whereas this was seen in only one of 11 with the three who had attained complete remissions in the past, creatinine р1 mg/dl (P = 0.022, Fisher's exact test). This showed any response to CCV. Three of four patients treated suggests that this treatment should not be used in patients with four previous regimens responded compared with one with compromised kidneys due to the possibility of fatal of 14 treated with more than four regimens (P = 0.02, toxicity or renal failure. Fisher's exact test). Neither of the patients with immunoWe conclude that although the combination of carboplablastic transformation and meningeal infiltration responded tin, cyclophosphamide, and etoposide at the doses used here either locally or systemically.
is tolerated well by patients with normal renal function, toxicity in patients with pre-existing renal dysfunction is substantial, and it should be avoided in patients with Outcome compromised renal function. This combination has poor As of July 1996, one of the responding patients was alive activity in the setting of disease relapsing after extensive with stable disease (partial remission) at 18 months, and previous therapy, but it may deserve further evaluation four of the non-responding patients were alive with proearly in the course of salvage therapy of myeloma. gressive disease at 8, 8, 13 and 18 months. Three of the responding patients and six of the non-responding patients died of relapsed or progressive disease at 2.5-15 months (median 7).
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